Infection of humans with hepatitis B virus (HBV) frequently results in suppression of hematopoiesis; in some cases this may lead to severe bone marrow failure. The mechanism whereby HBV infection affects hematopoiesis is unknown. In vitro exposure of human bone marrow to HBV results in a dose-dependent inhibition of erythroid (erythroid burst forming units, BFU-E; erythroid colony-forming units CFU-E), myeloid (colony-forming unitsgranulocyte macrophage CFU-GM), and lymphoid (CFU-[T-lymphocytic]-TL) hematopoietic stem cells. Inactivation or immunoabsorption of HBV from sera resulted in loss of HBVinduced inhibition of hematopoietic stem cells. De novo gamma interferon was not detectable in the supernatants of cultures of bone marrow cells with HBV. Antibodies to gamma interferon did not affect the suppression of hematopoietic stem cells by HBV. Hepatitis B surface antigen (HBsAg) was detected by immune electron microscopy in nuclei of greater than 70% of immature hematopoietic cells including myeloblasts, normoblasts, and lymphoblasts; granulocytes had mostly cytoplasmic HBsAg. Hepatitis B virus core antigen (HBcAg) was also detected in about 5% of HBV infected bone marrow cells by immunoperoxidase staining. These data indicate that HBV can infect hematopoietic cells and their progenitors, thus suggesting a wider range of tropism for HBV than previously reported. These results may provide a basis to study HBV infection in vitro, and the effects of HBV on hematopoiesis. 
Introduction
Despite the common belief that hepatitis B virus (HBV)' is exclusively hepatotrophic, recent evidence suggests that HBV can 1. Abbreviations used in this paper: BFU-E, burst-forming units, erythroid; CFU-E, colony-forming units, erythroid; CFU-GEMM, CFU- infect human hematopoietic cells. Romet-Lemonne and colleagues found that a small percentage ofbone marrow cells from four HBV-infected patients contained hepatitis B virus surface antigen (HBsAg) and hepatitis B core antigen (HBcAg). In addition, they established an HBV-containing lymphoblastoid cell line from the bone marrow of a patient with HBV infection (1) . Others have identified HBV DNA sequences in the peripheral blood cells of patients with HBV infection (2, 3) and in patients with acquired immunodeficiency syndrome (AIDS) (4) . Infection of hematopoietic cells by HBV may explain the moderate bone marrow failure as well as the rare cases of aplastic anemia observed in patients with HBV infection (5) . To determine the mechanism whereby HBV inhibits normal hematopoiesis, we studied the effect of HBV on the growth of bone marrow progenitor cells in vitro. Normal bone marrow cells (MNC) were exposed to HBV-containing sera and cultured to determine the effect of HBV infection on five classes of hematopoietic stem cells including granulocyte/macrophage (CFU-GM), erythroid (CFU-E, BFU-E), T loglo dilutions of human sera at 370C in 5% CO2 atmosphere for 20 h. The cells were harvested, washed three times, and assayed for CFU-GM, CFU-TL, BFU-E, CFU-E, and CFU-GEMM as follows:
CFU-GM. 2 X 105 MNC were assayed for CFU-GM in minimal essential medium (MEM)-alpha medium (Irvine Scientific, Irvine, CA), containing 0.3% agar, 20% FCS, and 10% phytohemagglutinin-stimulated leukocyte conditioned medium (PHA-LCM). CFU-GM were scored after 10 d of culture with colonies consisting of greater than 40 cells.
CFU-TL. 1 X l0 MNC were plated in eniched MEM-alpha medium containing 20% FCS, 15% bovine serum albumin (BSA), 5 X l0-' 2-mercaptoethanol (2ME), and 20% interleukin 2 (6). Colonies were scored after 7 d.
CFU-E, BFU-E, and CFU-GEMM. 2 X IO' MNC were cultured in Iscove's modified Dulbecco's medium in the presence of 0.8% methylcellulose, 30% FCS; 10% PHA-LCM, 1% deionized BSA (Sigma, St. Louis, MO) 5 X l0-e 2ME and 2 U/ml erythropoietin (Green Cross, Tokyo, Japan) for BFU-E and CFU-GEMM and 0.3 U/ml erythropoietin for CFU-E. BFU-E and CFU-GEMM were scored after 14 and 16 d of culture, respectively. CFU-E were scored after 7 d of culture.
Each assay consisted of I ml of the respective mixture plated in duplicate in 35-mm LUX tissue culture dishes (Miles Laboratories, Naperville, IL) and incubated at 370C in 5% CO2 and 95% humidity. The number of colonies formed from bone marrow incubated with HBV were compared to that incubated with normal AB+ control serum and the data expressed as percent inhibition. Each assay was run in triplicate and the results are reported as the mean number of colonies for a particular dilution of serum.
Inactivation ofHBV+ Sera
Heat inactivation. I Absorption ofsera with bone marrow cells. 5 X l05 MNC in RPMI 1640 were incubated with an equal volume of sera for 2 h at 4VC. The cells were pelleted at 400 g and the supernatant removed.
Monoclonal anti-gamma interferon antibodies. Monoclonal antigamma interferon antibodies with a neutralizing effect of 1,600 nU/unit gamma interferon were obtained from Dr. Jan T. Vilcek (7) . Bone marrow cells were incubated with HBV+ serum and a volume ofantibody capable of neutralizing 40 U/ml of gamma interferon. After 20 h of incubation, the MNC were washed twice and assayed for CFUJ-E and CFU-GM as described.
HBV DNA assay
The sensitivity of this assay is 2.8 X 104 HBV DNA molecules per 50 Ml serum. The preparation ofthe serum samples was performed as described (8) , Biodyne Nylon Membrane (Pall-Ultra Fine Corp, Glen Cove, NY) was used instead of nitrocellulose. The membranes were prehybridized and hybridized to 32P-labeled HBV DNA by standard techniques (9) . The filters were washed at room temperature with 2 X standard saline citrate (SSC) (1 X SSC = 0.15 M NaCl, 0.0 15 M sodium citrate pH 7.0) with 0.5% SDS for 5 min, then 2 X SSC with 0.1% sodium dodecyl sulfate (SDS) for 15 min, then twice in 0.1 X SSC with 0.5% SDS at 680C for 1 h each. The filters were air-dried and autoradiographed overnight and for 7 d at -70'C using Kodak X-Omat XAR film (Eastman Kodak Co., Rochester, NY) and a Cronex Lightning-Plus enhancing screen (DuPont, Wilmington, DE). 32P-labeled HBV were produced by nick translation using standard techniques (9) . The 32P-labeled HBV DNA probe (sp act 1-4 X 108 cpm/Mg DNA) did not cross hybridize with pBR322 DNA. Preparations were examined with an electron microscope. Black grains appeared in cells containing HBsAg.
Immunoperoxidase detection ofHBcAg 1 X 106 MNC were incubated with sera as described above and then transferred to a microscope slide using a cytospin (Shandon-Southern, England). The cells were then stained for HBcAg by the protocol and reagents of the DAKO peroxidase antiperoxide (PAP) kit for HBcAg (DAKO Corp., Santa Barbara, CA) (12) . Samples were air-dried, incubated with 3% H202 in methanol for 5 (Fig. 1) . Although the absolute number of colonies in each assay varied for different bone marrow specimens, percent inhibition was internally consistent for each experiment. Incubation of bone marrow cells with serial logl0 dilutions of HBV containing sera resulted in the gradual loss of the HBV-mediated suppression. Inhibition of CFU-GM and CFU-TL was still observed using sera diluted 1:100. Other sera that had higher concentrations of HBV DNA inhibited the number ofCFU-GM and BFU-E by as much as 100% compared to control (data not shown). CFU-E was also inhibited by HBV DNA+ sera. Undiluted HBV DNA+ sera from three patients inhibited CFU-E by 38±7, 72±3, and 100±0%. In a preliminary study, CFU-GEMM was also found to be inhibited by 75% of control by undiluted HBV serum. (Exposure to control serum gave 8±2 colonies per 2 X I05 MNC, while undiluted HBV sera produced 2±1 CFU-GEMM per 2 X 105 MNC.)
The effect of preincubation time on subsequent BFU-E colony formation by two different HBV DNA containing sera is illustrated in Fig. 2 . Although no inhibition of BFU-E was observed after 3 h of preincubation with undiluted serum 1, complete suppression was seen after 20 h preincubation of undiluted serum but not serum diluted 1:100. Serum 2, which contained a tenfold higher concentration of HBV DNA, completely inhibited BFU-E after 3 h incubation when undiluted, but not at a 1:1,000 dilution. Similar results were obtained with CFU-GM and CFU-E.
Nine HBV DNA negative sera from patients with chronic non-A, non-B hepatitis, hepatitis A, Epstein-Barr virus-related hepatitis, hepatoma and healthy normal volunteers had no significant effect on hematopoietic stem cells (<20% inhibition). In these experiments, significant inhibition of CFU-GM assay by >30% correlated with the presence in serum of HBV DNA sequences. CFU-GM were inhibited by all HBV DNA positive sera whether or not circulating mononuclear cells from the patient contained HBV DNA (Table I) .
To determine ifthe HBV virion is responsible for inhibition ofCFU-GM, HBV DNA positive sera were treated to inactivate of HBV DNA positive sera on CFU-GM. In contrast, dialysis of HBV DNA+ sera against PBS did not suppress CFU-GM. Serum depleted of HBV DNA following passage through an anti-HBs immunoabsorption column no longer inhibited CFU-GM. The HBV DNA containing eluate recovered from the column markedly suppressed CFU-GM. The inhibitory activity of HBV containing sera thus coincided with HBV infectivity and the presence of HBsAg immunoreactivity and of HBV DNA.
To investigate whether antibodies to HLA might account for inhibition of CFU-GM, HBV DNA+ serum was absorbed against bone marrow cells from the same donor used in the stem cell assays. Preabsorption did not abrogate the inhibitory effect ofHBV DNA+ serum on CR1-GM. Additional evidence against a role ofanti-HLA antibodies is the finding that the same serum inhibited progenitors from individuals of different HLA types and that different HBV DNA+ sera inhibited bone marrow from a single donor. As indicated, HBV DNA-sera from individuals had no effect on CFU-GM.
Gamma interferon can inhibit CFU-GM in vitro (13) and may play a role in the suppression of hematopoiesis in some cases of aplastic anemia (14, 15) . The HBV DNA+ sera we studied typically contained 5-15 U/ml of gamma interferon vs. 5 U/ml in normal sera (as determined by the VSV/WISH assay [16] ). It was therefore necessary to determine whether the observed inhibition of bone marrow progenitor cells with HBV DNA+ sera was mediated by gamma interferon. Incubation of HBV DNA+ serum with a monoclonal anti-gamma interferon antibody prior to addition of bone marrow cells did not affect the serum's ability to inhibit CFU-GM or CFU-E colony formation (Fig. 4) . Furthermore, preincubation of bone marrow cells with 10 to 1,000 U/ml gamma interferon for 20 h did not alter the number of CFU-GM (data not shown). Finally, the concentration ofgamma interferon recovered from these cultures decreased with incubation time consistent with the conclusion that gamma interferon was not induced during culture of bone marrow cells with HBV.
Having established that HBV can inhibit hematopoiesis in vitro, we next determined if HBV-associated antigens could be detected in bone marrow cells exposed to HBV containing sera. Bone marrow was incubated with HBV DNA+ sera, washed, incubated with murine anti-HBs antibodies or hyperimmune anti-HBs sera, and examined for indirect immunofluorescence by fluorescence microscopy or using a FACS. 1 To better define the population of MNC containing viral antigens, immunoelectron microscopic analyses of bone marrow cells cultured with and without HBV DNA+ serum were performed. Surface labeling with murine monoclonal anti-HBs antibodies was only observed in <10% of the myeloperoxidasepositive myeloblasts and myelocytes. Lymphocytes and erythrocyte precursors did not have HBsAg on their surface. In contrast, intracellular labeling with monoclonal anti-HBs antibodies was detected in nuclei and cytoplasm of all nucleated cells examined. The labeling pattern of the nucleus and cytoplasm was different among the various hematopoietic cell types (Table II) . Greater than 70% of nuclei of myeloblasts, normoblasts, and lymphocytes were HBsAg+; granulocytes contained predomi- was incubated with MNC and HBV as described in Methods. The mean number of colonies of the control were 456± (95% CI) for CFU-E and 47±3 (95% CI) for CFU-GM. In addition to HBV, other types of acute viral infections, including non-A, non-B hepatitis, hepatitis A, and Epstein-Barr virus hepatitis are associated with bone marrow suppression. However, sera from patients with these infections have no effect on bone marrow progenitor cells. Their inability to suppress bone marrow progenitor cells may be related to the presence of low concentrations ofvirus. Indeed, it has been shown that during the clinical phase of acute hepatitis A infection, the serum concentration of virus is very low. The lack of an inhibitory effect by sera of patients with other infectious agents may be analogous to the gradual loss ofinhibition observed with the serial dilution of HBV DNA+ sera.
In their study of a parvovirus-like agent and its effect on hematopoiesis, Young et al. reported that acute phase sera from patients with HBV-associated hepatitis failed to inhibit bone marrow progenitor cells in vitro (19) . This lack of effect may be attributed to the exposure of bone marrow cells only to a 1:100 dilution of sera. As demonstrated in Figs. 1 and 2 , the inhibitory effect of HBV on hematopoiesis may be readily diluted out at a 1:100 concentration ofsera containing only a moderate amount of HBV DNA. Sera that contain the parvovirus-like agent described by Young et al. (19) inhibit CFU-E at greater dilutions than sera that contain HBV. The greater potency of the parvovirus-like agent containing sera may be a reflection ofa higher concentration of active virus in serum as compared to that of HBV. Gamma interferon has been demonstrated to be produced by the peripheral blood mononuclear cells of patients who have aplastic anemia. Some patients with aplastic anemia also have very high concentrations of gamma interferon in their serum. This has led to the hypothesis that gamma interferon may be a mediator ofthe hematopoietic suppression that occurs in aplastic anemia (14, 15) . However, our results suggest that HBV suppression of colony formation is not mediated by gamma interferon. The addition of monoclonal anti-gamma interferon antibody did not affect HBV suppression of CFU-E and CFU-GM. It should be emphasized furthermore, that bone marrow cells were preincubated with HBV sera prior to cell culture, and thus only exposed to low levels of gamma interferon (10-20 U/ ml) for 18 to 24 h. We have demonstrated that preincubation of bone marrow cells with gamma interferon up to 1,000 U/ml did not affect colony formation. These results are similar to those reported by Toretsky et al. (20) who showed that transient exposure to bone marrow cells to gamma interferon did not significantly suppress colony formation. A dose-dependent suppression ofcolony formation was only observed when gamma interferon was added in continuous culture to bone marrow cells (unpublished observations, 13, 15, 20) .
Though both alpha and gamma interferon are induced by acute viral infections, a putative role for alpha interferon in HBV suppression of hemopoiesis was not studied. It should be noted that the dose-response suppression of colony formation by alpha interferon is similar to gamma interferon for CFU-GEMM, BFU-E, and day 7 CFU-GM. Day 14 CFU-GM, which were assayed in the present study, were significantly less sensitive to alpha interferon (13). Thus, while alpha interferon's role in the suppression of hematopoiesis observed by HBV in vitro cannot be excluded, it is unlikely.
Since hematopoietic cells are easily obtained, and because there are extensive in vivo and in vitro data regarding their growth, progenitor-progeny relationships, and growth-factor requirements, the effects of HBV on bone marrow progenitor cells can be readily studied in vitro. To date, there is no in vitro model to examine HBV infection of human hepatocytes and hepatoma cells. The infection of human bone marrow cells with HBV thus may provide a model to study the cellular and molecular events associated with HBV infection.
